383859-43-6

Basic information

• Product Name: (4aR,7S,8aS)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-ol
• Synonyms: (4aR,7S,8aS)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-ol
• CAS NO: 383859-43-6
• Molecular Weight: 236.268
• Mol File: 383859-43-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (4aR,7S,8aS)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (4aR,7S,8aS)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-ol(383859-43-6)
• EPA Substance Registry System: (4aR,7S,8aS)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-ol(383859-43-6)

Safety Data

• Hazardous Substances Data: 383859-43-6(Hazardous Substances Data)

Upstream product

• 152613-20-2 (4aR,7R,8aS)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-ol 
• 125901-90-8 (2R,3S)-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-ol 
• 149342-25-6 ((2R,3S)-3-acetoxy-3,6-dihydro-2H-pyran-2-yl)methyl acetate 
• 2873-29-2 D-glucal triacetate 

Downstream Products

• 701917-50-2 1,5-Anhydro-2-azido-4,6-O-benzylidene-2,3-dideoxy-D-ribo-hexitol 
• 1398569-96-4 (4aR,7S,8aS)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl methanesulfonate 
• 383859-49-2 1′,5′-anhydro-2′-(N(6)-benzoyl-adenin-9-yl)-2′,3′-dideoxy-6′-O-monomethoxytrityl-D-ribohexitol 
• 383859-47-0 1,5-anhydro-4,6-di-O-pivaloyl-2-O-tosyl-3-deoxy-D-mannitol 
• 383859-48-1 3′-deoxy-2′-(N(6)-benzoyladenin-9-yl)-1′,5′-anhydro-D-ribo-hexitol 
• 383859-44-7 1,5-anhydro-2-O-tosyl-3-deoxy-D-mannitol 

Relevant articles and documents

Hybridization between "six-membered" nucleic acids: RNA as a universal information system

(Matrix Presented) Within the polyA:polyT recognition system, cross-pairing between several nucleic acids with a phosphorylated six-membered carbohydrate (mimic) as repeating unit in the backbone structure has been observed. All investigated nucleic acids (except for β-homo-DNA) hybridize with RNA, leaving RNA as a versatile biopolymer for informational transfer.

NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.